Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering

  title={Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol Lowering},
  author={Carl P. Sparrow and Charlotte A. Burton and Melba Hernandez and Steven S. Mundt and H. Carlijne Hassing and Sushma Patel and Raymond L Rosa and Anne Hermanowski‐Vosatka and Pei-ran Wang and Donghui Zhang and Larry Peterson and Patricia A. Detmers and Yu-sheng Chao and Samuel D. Wright},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association},
  • C. SparrowC. Burton S. Wright
  • Published 1 July 2000
  • Biology, Medicine, Chemistry
  • Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association

Figures from this paper

Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation.

Histopathological examination of the footpad skin biopsies revealed that simvastatin, dose-dependently and comparablly to indomethacin, reduced polymorphonuclear leucocyte infiltration and supported the hypothesis that simVastatin has an acute anti-inflammatory activity.

Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol

In primates, these results provide further support for the beneficial effect of statins on plaque inflammation and stability in addition to cholesterol lowering.

Effect of Different Doses of Pravastatin on Formalin-Induced Inflammatory Response in Mice

The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) have been unequivocally shown to reduce cardiovascular morbidity and mortality. Their lipid-lowering actions are by

Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.

Rsuvastatin attenuates arterial thrombosis and neointima formation, and it may stabilise vascular lesions developing after endothelial injury in mice, independent of systemic lipid lowering.

Simvastatin Reduces Neointimal Thickening in Low-Density Lipoprotein Receptor–Deficient Mice After Experimental Angioplasty Without Changing Plasma Lipids

Simvastatin modulates vascular repair after injury in the absence of lipid-lowering effects and may lead to new understanding of the actions of statins and novel therapeutic interventions for preventing restenosis.

Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering

Objective—This study sought to determine whether simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, has stabilizing effects on vulnerable atherosclerotic plaques that are

A Novel Anti-Inflammatory Role for Simvastatin in Inflammatory Arthritis 1

It is reported that simvastatin markedly inhibited not only developing but also clinically evident collagen-induced arthritis in doses that were unable to significantly alter cholesterol concentrations in vivo.

Treatment With Simvastatin Suppresses the Development of Experimental Abdominal Aortic Aneurysms in Normal and Hypercholesterolemic Mice

Treatment with simvastatin suppresses the development of experimental AAAs in both normal and hypercholesterolemic mice and the mechanisms are independent of lipid-lowering and include preservation of medial elastin and smooth muscle cells, as well as altered aortic wall expression of MMPs and their inhibitors.



A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.

This is the first report of a decrease in eNOS mRNA in Atherosclerosis after removal of dietary cholesterol and a reversal of it by a HMG-CoA reductase inhibitor, which may contribute to the regression of atherosclerosis.

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.

  • M. EndresU. Laufs J. Liao
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 1998
The results suggest that HMG-CoA reductase inhibitors provide a prophylactic treatment strategy for increasing blood flow and reducing brain injury during cerebral ischemia.

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Findings suggest that HMG CoA reductase inhibitors may have beneficial effects in atherosclerosis beyond that attributed to the lowering of serum cholesterol by increasing ecNOS activity.

Arginine: a new therapy for atherosclerosis?

Dietary arginine supplementation markedly reduced the development of intimal lesions and xanthoma formation was abolished, adding further weight to the accumulating evidence that dietary supplementation of arginines inhibits atherogenesis.

Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.

The results indicate that, when administered for a longer period, the drug showed no hypocholesterolemic activity in these species under either normo- or hypercholesterolems, except for rats treated with the detergent Triton WR-1339.

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit.

It is indicated that captopril has a potent antiatherosclerotic action in the Watanabe heritable hyperlipidemic rabbit.

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.

Evidence is provided that HMG-CoA reductase inhibitors are potent and effective cardioprotective agents that inhibit leukocyte-endothelial cell interactions and preserve cardiac contractile function and coronary perfusion after myocardial ischemia and reperfusion.

The antioxidant butylated hydroxytoluene protects against atherosclerosis.

The results are in accord with the contention that oxidative modification of lipoproteins is important for the development of atherosclerosis and that antioxidants may have a protective effect and other explanations cannot be completely excluded.

Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.

Results suggest that aortic accumulation of LO(O)H is not required for, nor is alpha-tocopherol depleted during, the initiation and progression of atherogenesis in Watanabe heritable hyperlipidemic rabbits.